Navigation Links
Lung Cancer Alliance Releases 4th Annual Report Card on Lung Cancer
Date:11/6/2008

Slight Improvements - But Overall Failing Grades

WASHINGTON, Nov. 6 /PRNewswire-USNewswire/ -- For the fourth year in a row, Lung Cancer Alliance (LCA) marked the start of Lung Cancer Awareness Month with the release of its "Report Card on Lung Cancer", a national assessment of progress being made in the fight against lung cancer. For 2008, LCA noted slight improvements, but overall, failing grades continued.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081016/LCALOGO)

"The good news is that we are finally seeing slight improvements - but make no mistake, the overall grades remain unsatisfactory," said Laurie Fenton Ambrose, LCA President & CEO.

"We must and can do better for all those living with or at risk for lung cancer - a disease that remains the most stigmatized, least funded and ignored of all the leading cancers," she said.

The 2008 Report Card on Lung Cancer grades seven categories to evaluate progress in the efforts made to eradicate this disease. The Report Card noted slight improvements in federal research funding and advances in treatment and diagnostic options, including clinical trials. But overall, funding for public health research and early disease intervention remain anemic and translating new discoveries to patient treatment faces daunting challenges.

"The most significant development was seeing LCA's top priority to increase research funding signed into law in September," continued Fenton-Ambrose. "The Department of Defense has now established a $20 million lung cancer research pipeline and we will work to increase this funding next year".

"In addition," she said, "we are heartened to see encouraging trends toward more personalized clinical trials and vaccines to prevent lung cancer recurrence, along with stepped up research in targeted drug therapies, genetic profiling and biomarkers in blood and sputum.

"But we continue to lag far behind in research funding, early disease intervention, and clinical trial awareness and participation", said Fenton-Ambrose. "Not until the public health establishment commits to making lung cancer a national public health priority will major advancements be fully realized."

The 2008 Report Card on Lung Cancer is widely distributed among public policy leaders, medical professionals and health care associations working to improve outcomes for lung cancer.

To view the complete 2008 Report Card on Lung Cancer visit http://www.lungcanceralliance.org

Lung Cancer Alliance, http://www.lungcanceralliance.org, is the only national non profit dedicated exclusively to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to reversing decades of stigma and neglect by empowering those with or at risk for lung cancer, elevating awareness, and changing health policy.

Media Contact:

Kay Cofrancesco

kay@lungcanceralliance.org

202-463-2080


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Migraine Might Lower Breast Cancer Risk
2. Age is not a key factor in cancer survival, but clinical trials exclude older patients
3. How women can improve their quality of life after breast cancer treatment
4. Scientists Debate Dietary Supplements and Cancer Risk at AICR Conference
5. Three Women in Health Crises Go Online to Form Lifelong Friendships : Mothers of Boys with Cancer Find Support, Encouragement and Each Other at CarePages.com
6. Minority patients discouraged from cancer screening by negative messages
7. Migraines associated with lower risk of breast cancer
8. Study finds racial disparities increasing for cancers unrelated to smoking
9. Therapy may block expansion of breast cancer cells
10. Risk assessment tool not reliable predictor for some women at high risk of breast cancer
11. Technique Preserves Future Fertility in Girls With Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Virginia (PRWEB) , ... September 20, 2017 , ... ... Flex Pure Clinical Plus Coating System for clients that rely on safety and ... the growth of microorganisms. , Silver has been used for centuries for its ...
(Date:9/20/2017)... ... September 20, 2017 , ... Mirror Mirror Beauty Boutique ... Look Awesome This Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon ... Mirror Mirror Beauty Boutique is Houston’s largest CoolSculpting provider, holding the ...
(Date:9/20/2017)... ... September 20, 2017 , ... Each year Athletic Trainers from ... Trainers’ Association Annual Clinical Symposium and Expo. New research is revealed, evidence based ... Trainers are acknowledged by their peers with accolades and highly prestigious awards. This ...
(Date:9/20/2017)... ... September 20, 2017 , ... Medicare doesn’t have the authority ... gouging for their prescription drugs, according to a new comparison of drug plans ... our behalf, there’s no consistency in drug pricing among drug plans,” states TSCL’s ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Finn Mouseson”: follows the exciting story ... average life. This mouse sets out on a journey that will show that friends ... the creation of newly published author and illustrator, Melody Gersonde-Mickelson, who has earned a ...
Breaking Medicine News(10 mins):
(Date:9/7/2017)... -- Eli Lilly and Company (NYSE: LLY ... more efficiently focus resources on developing new medicines ... reductions, including those from a U.S. voluntary early ... positions. With the streamlining efforts ... $500 million that will begin to be realized ...
(Date:9/7/2017)...   BioLife Solutions , Inc. (NASDAQ: BLFS ... grade cell and tissue hypothermic storage and ... , President and CEO, will be presenting at two investment ... Renshaw 19 th Annual Global Investment Conference on Tuesday, ... time). The conference is being held at the New York ...
(Date:9/6/2017)... Sept. 6, 2017 Eli Lilly and Company ... present new data for galcanezumab and lasmiditan, two investigational ... International Headache Society (IHC) taking place Sept. 7-10 in ... will highlight new, long-term data from an open-label study ... galcanezumab (120 mg and 240 mg) for the prevention ...
Breaking Medicine Technology: